Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is an open-label trial of an omega-3 fatty acid for symptoms of the schizophrenia prodrome.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ethyl-eicosapentaenoic acid | Drug | 2 mg per day |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| conversion to psychosis | one year |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Scott W Woods, MD | Yale University | Principal Investigator |
Not provided
Not provided
| ID | Term |
|---|---|
| C035276 | eicosapentaenoic acid ethyl ester |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided